Clinical Trial Update: PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a PD-1 inhibitor combined with azacytidine, homoharringtonine, cytarabine, and G-CSF for refractory or relapsed acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• G-CSF (granulocyte colony-stimulating factor)
• Homoharringtonine (homoharringtonine)
• PD-1 inhibitor
• azacytidine (azacitidine)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Immunotherapy, Refractory Leukemia | Phase 3 | Status: UNKNOWN